Barclays’s Altimmune ALT Stock Holding History

Barclays’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-25,000	Closed	-$255K	–	4836
2024 Q1	$255K	Buy	+25,000	New	+$254K	﹤0.01%	3984

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Barclays's ALT Position: Q1 2026 in Review

Barclays reduced its Altimmune (ALT) stake by 52% in Q1 2026, selling an estimated $882K and leaving 192,871 shares worth $594K. The position accounts for ﹤0.01% of the portfolio, ranked #3082.

Barclays first reported a position in ALT in Q2 2013 and has held it in 30 quarters since. The position peaked at $12.5M in Q2 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

Barclays held 192,871 shares of Altimmune worth $594K as of Q1 2026.
Barclays sold 207,724 Altimmune shares in Q1 2026, an estimated $882K.
Altimmune made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3082 holding.
Barclays first reported a position in Altimmune in Q2 2013 and has held it in 30 quarters since.
Barclays's Altimmune position peaked at $12.5M in Q2 2022.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.